I agree that this site is using cookies. You can find further informations here.
X
Breder, Valeriy
49  results:
Search for persons X
?
1

Durvalumab plus gemcitabine and cisplatin in advanced bilia..:

Burris III, Howard A ; Okusaka, Takuji ; Vogel, Arndt...
The Lancet Oncology.  25 (2024)  5 - p. 626-635 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Efficacy and Safety of Atezolizumab plus Bevacizumab versus..:

Finn, Richard S. ; Galle, Peter R. ; Ducreux, Michel...
Liver Cancer.  , 2024
Link: https://doi.org/10.1159/..
 
?
3

Durvalumab or placebo plus gemcitabine and cisplatin in par..:

Oh, Do-Youn ; He, Aiwu Ruth ; Bouattour, Mohamed...
The Lancet Gastroenterology & Hepatology.  9 (2024)  8 - p. 694-704 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Tu1578 IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS ..:

Finn, Richard S. ; Breder, Valeriy ; Vogel, Arndt...
Gastroenterology.  166 (2024)  5 - p. S-1738 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Plain language summary of the HIMALAYA study: tremelimumab ..:

Abou-Alfa, Ghassan K ; Lau, George ; Kudo, Masatoshi...
Future Oncology.  19 (2023)  38 - p. 2505-2516 , 2023
Link: https://doi.org/10.2217/..
 
?
6

Lenvatinib plus pembrolizumab versus lenvatinib plus placeb..:

Llovet, Josep M ; Kudo, Masatoshi ; Merle, Philippe...
The Lancet Oncology.  24 (2023)  12 - p. 1399-1410 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Pembrolizumab as Second-Line Therapy for Advanced Hepatocel..:

Merle, Philippe ; Kudo, Masatoshi ; Edeline, Julien...
Liver Cancer.  12 (2023)  4 - p. 309-320 , 2023
Link: https://doi.org/10.1159/..
 
?
8

Updated efficacy and safety data from IMbrave150: Atezolizu..:

Cheng, Ann-Lii ; Qin, Shukui ; Ikeda, Masafumi...
Journal of Hepatology.  76 (2022)  4 - p. 862-873 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Atezolizumab + bevacizumab versus sorafenib in patients wit..:

Ducreux, Michel ; Zhu, Andrew ; Qin, Shukui...
Journal of Hepatology.  73 (2020)  - p. S121 , 2020
Link: https://doi.org/10.1016/..
 
?
10

Health‐related quality‐of‐life impact of pembrolizumab vers..:

Ryoo, Baek‐Yeol ; Merle, Philippe ; Kulkarni, Amit S....
Cancer.  127 (2020)  6 - p. 865-874 , 2020
Link: https://doi.org/10.1002/..
 
?
11

RADIATION THERAPY IN MULTIMODAL TREATMENT OF PATIENTS WITH ..:

Borisova, Tatyana ; Tkachev, S. ; Ivanov, S....
Problems in oncology.  66 (2020)  5 - p. 465-471 , 2020
Link: https://doi.org/10.37469..
 
?
12

BRAIN METASTASES AFTER LIVER TRANSPLANTATION IN PATIENTS WI..:

Natrusova, M. ; Breder, Valeriy ; Dzhanyan, Irina...
Problems in oncology.  65 (2019)  6 - p. 877-882 , 2019
Link: https://doi.org/10.37469..
 
?
13

EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QU..:

Laktionov, Konstantin ; Arzumanyan, Alla ; Bolotina, Larisa...
Problems in oncology.  65 (2019)  1 - p. 99-105 , 2019
Link: https://doi.org/10.37469..
 
?
14

LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR..:

Laktionov, Konstantin ; Reutova, Yelena ; Kormosh, Natalya..
Problems in oncology.  65 (2019)  3 - p. 386-392 , 2019
Link: https://doi.org/10.37469..
 
?
15

TRANSARTERIAL CHEMOEMBOLIZATION(TACE) EFFICACY IN PATIENTS ..:

Breder, Valeriy ; Dolgushin, Boris ; Kukushkin, Anatoliy...
Problems in oncology.  64 (2018)  6 - p. 793-798 , 2018
Link: https://doi.org/10.37469..
 
1-15